|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:G04BE09
|
|
gptkbp:bioavailability
|
15%
|
|
gptkbp:brand
|
gptkb:Staxyn
gptkb:Levitra
|
|
gptkbp:CASNumber
|
224785-91-5
|
|
gptkbp:chemicalFormula
|
piperazine derivative
|
|
gptkbp:contraindication
|
concurrent nitrate therapy
severe cardiovascular disorders
|
|
gptkbp:discoveredBy
|
gptkb:Bayer_Pharmaceuticals
|
|
gptkbp:drugClass
|
phosphodiesterase type 5 inhibitor
|
|
gptkbp:eliminationHalfLife
|
4-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstPassMetabolism
|
yes
|
|
gptkbp:form
|
orally disintegrating tablet
film-coated tablet
|
|
gptkbp:hasMolecularFormula
|
C23H32N6O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vardenafil
|
|
gptkbp:interactsWith
|
gptkb:milk
CYP3A4 inhibitors
nitrates
alpha-blockers
|
|
gptkbp:IUPACName
|
2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits phosphodiesterase type 5
|
|
gptkbp:meltingPoint
|
192-193°C
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP3A5, CYP2C9)
|
|
gptkbp:patent
|
gptkb:Bayer
|
|
gptkbp:pregnancyCategory
|
Not for use in women
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
110634
99313
|
|
gptkbp:relatedTo
|
gptkb:avanafil
gptkb:sildenafil
gptkb:tadalafil
|
|
gptkbp:riskFactor
|
hypotension
priapism
visual disturbances
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
headache
nasal congestion
dyspepsia
flushing
|
|
gptkbp:UNII
|
07HA4YKV1G
|
|
gptkbp:usedFor
|
erectile dysfunction
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|